Weight-loss Drug Lorcaserin managed not to get the approval from the FDA

altNewsPage

Published 25 October 2010

The battle for the pills licensed A Big Stakes
D Sharon Pruitt

There are a dozen years since the u.s. Food and Drug Administration green lit a new prescription weight loss pill.Later to be released can be returned.

The news was released on 23 October 2010 and that another failure to make the grade was held.This time it is lorcaserin is the loss of weight of wanna-be-on-the-market drugs rejected as captured by the Food and Drug Administration (FDA) of the United States.

Without FDA approving drug new application (NDA a pharmaceutical company) drug goes nowhere and all that effort research effacé.Il just ask Eisai Inc., manufacturers of lorcaserin and the Arena pharmaceuticals, although not asking anything on as they say, they continue to try to obtain approval from the FDA for the product that they naturally believe in the.

Money and health game

The stakes are high, when it wants to be granted the right to order the marché.Le weight loss drug number of buyers of a drug with weight loss properties which does not damage the health is in a world which adds people more overweight by the minute, astronomical.

The American Medical Association (AMA), explains almost one-third of the u.s. adult population is obese and the money spent on weight loss in America each year tens of billions, therefore a loss weight drugs is a license to print money. arena and Eisai felt they have crossed the T and with the same graduation present their results and the NDA, better they could, but they did not.

Saturday, the FDA has sent to Arena and Eisai Inc. a full letter of response (CSF) transformant.Il is the first official word from the FDA on lorcaserin a panel of experts from outside also denied the drug in September.

FDA turns Down Drug Lorcaserin Arena

The reasons given by the FDA, include any capacity loss of weight in obese persons who have no diabetes drug is "marginal" and continue to have concerns about tumours which has developed during the early stages of their press release, Arena, essais.Dans rat President and CEO Jack Lief put a spin positive on the list.

"This is an important step for us to approval by the FDA of lorcaserin," writes Lief."While the complete response letter offers us the recommendations of the Agency, we intend to meet with the FDA for more clarity on the path to approval and timing." We will work with the Agency to resolve problems with our NDA as quickly as possible.?

Arena points out that the FDA had written in his letter "of evidence may be provided to alleviate the concerns of the clinical relevance of findings tumours in rats, additional clinical studies may be required to obtain a more robust assessment of benefit-risk profile of lorcaserin." The FDA is entirely in their mandate at the request of long and costly studies.

Onexa and Mérida also in new weight loss drug

Onexa is another drug for approval also rejected by an external panel of experts and who expect to hear this week by the FDA.Earlier this month following drug loss weight Merida was fired market concerns caused adverse events including heart attack and stroke.

Bar sets for drug loss weight claim properties

Thomas Gryta Dow Jones Newswires, in an article in the Wall Street Journal Monday, pointed out that this latest release "confirms the bar regulatory of these therapies, something which can augured well for others to do the same effort".

Analyst Elemer Piros New-yorkais Rodman and Renshaw, said Gyrta FDA panel discussions that took place end investment quoted Gyrta clearly seek drugs which have a level of security comparable to the diet and exercise.

"We've practically written off the coast of lorcaserin and Qnexa for these reasons," Piros said Gryta, adding that the potential market for drugs is so great that, in the words of the Gryta, it follows "unbearable scrutiny" FDA to corporations and applying drugs.

Sources

• Scene press release. "FDA issues complete response for Lorcaserin letter request for drug Nouvelle.publié October 23 2010, accessed October 25
• Gryta, Thomas. "?Diet Drug denial Reflète High Bar to deal the obesity arena? 25 October published, accessed on the same day; Wall Street Journal
• Hunter, Aina. ""Diet pill Lorcaserin is blow inch Down from the FDA's" 25 October published, accessed on the same day; CBS News.com/Health

Related Office 101 Story.

Best weight loss program is you

Copyright Marcus Hondro .Contacter the author for permission to republish.

?

?

This entry transmitted via the service for full-text RSS - if this is your content and you read on someone to another site, please read our FAQ page fivefilters.org/content-only/faq.php
Article five filters features: After Hiroshima - non-rapport Cancer Catastrophe of Fallujah.

View the original article here